Mahabadi AA, Mohlenkamp S, Lehmann N, et al. CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. J Am Coll Cardiol Img. 2017;10:143 53. S4.4.4.1-11. Mortensen MB, Fuster V, Muntendam P, et al. A simple disease- guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage study. J Am Coll Cardiol. 2016;68:881 91. S4.4.4.1-12. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623 30. S4.4.4.1-13. Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71:85 94. S4.4.4.1-14. Bell SP, Orr NM, Dodson JA, et al. What to expect from the evolving field of geriatric cardiology. J Am Coll Cardiol. 2015;66:1286 99. S4.4.4.1-15. Fleg JL, Forman DE, Berra K, et al. Secondary prevention of ath- erosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation. 2013;128:2422 46. S4.4.4.1-16. Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications to combat polypharmacy. Ther Adv Drug Saf. 2015;6:212 33. S4.4.4.1-17. Qi K, Reeve E, Hilmer SN, et al. Older peoples attitudes regarding polypharmacy, statin use and willingness to have statins depre- scribed in Australia. Int J Clin Pharm. 2015;37:949 57. S4.4.4.1-18. Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascu- lar drugs: challenges for research and for patient care. J Am Coll Cardiol. 2015;66:1273 85. S4.4.4.1-19. Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017;177:955 65. S4.4.4.1-20. Odden MC, Pletcher MJ, Coxson PG, et al. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 yearsorolderintheUnitedStates.AnnInternMed.2015;162:533 41. 4.4.4.2. Young Adults (20 to 39 Years of Age) S4.4.4.2-1. Strong JP, Malcom GT, Oalmann MC, et al. The PDAY Study: natural history, risk factors, and pathobiology. Pathobiological Determinants of Atherosclerosis in Youth. Ann N Y Acad Sci. 1997;811:226 35.; discussion 35 7. S4.4.4.2-2. McGill HC Jr, McMahan CA, Herderick EE, et al. Effects of coro- nary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 2000;20:836 45. S4.4.4.2-3. Williams RR, Hopkins PN, Hunt SC, et al. Population-based fre- quency of dyslipidemia syndromes in coronary-prone families in Utah. Arch Intern Med. 1990;150:582 8. S4.4.4.2-4. McGill HC Jr, McMahan CA, Malcom GT, et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 1997;17:95 106. CLINICAL STATEMENTS AND GUIDELINES S4.4.4.2-5. Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipid- emia. Am J Cardiol. 2012;110:823 5. S4.4.4.2-6. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med. 2003;163:1966 72. S4.4.4.2-7. Domanski M, Lloyd-Jones D, Fuster V, et al. Can we dramatically reduce the incidence of coronary heart disease? Nat Rev Cardiol. 2011;8:721 5. S4.4.4.2-8. Durrington PN, Soran H. Cholesterol levels should play a more important role in identifying statin recipients. Circulation. 2017;135:627 9. S4.4.4.2-9. Thanassoulis G, Pencina MJ, Sniderman AD. The benefit model for prevention of cardiovascular disease: an opportunity to har- monize guidelines. JAMA Cardiol. 2017;2:1175 6. S4.4.4.2-10. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular dis- ease. N Engl J Med. 2012;366:321 9. S4.4.4.2-11. Lehr AL, Driver SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505 6. S4.4.4.2-12. Omura JD, Watson KB, Loustalot F, et al. Primary care providers awareness of physical activity-related intensive behavioral coun- seling services for cardiovascular disease prevention. Am J Health Promot. 2018. 890117118784226. S4.4.4.2-13. Domanski MJ, Fuster V, Diaz-Mitoma F, et al. Next steps in primary prevention of coronary heart disease: rationale for and design of the ECAD trial. J Am Coll Cardiol. 2015;66:1828 36. S4.4.4.2-14. Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391 9. 4.4.4.3. Children and Adolescents S4.4.4.3-1. Iannuzzi A, Licenziati MR, Vacca M, et al. Comparison of two diets of varying glycemic index on carotid subclinical atherosclerosis in obese children. Heart Vessels. 2009;24:419 24. S4.4.4.3-2. Murphy EC, Carson L, Neal W, et al. Effects of an exercise inter- vention using Dance Dance Revolution on endothelial function and other risk factors in overweight children. Int J Pediatr Obes. 2009;4:205 14. S4.4.4.3-3. Pratt RE, Kavey RE, Quinzi D. Combined dyslipidemia in obese children: response to a focused lifestyle approach. J Clin Lipidol. 2014;8:181 6. S4.4.4.3-4. de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat adolescents at risk for cardiovascular disease. Obesity (Silver Spring). 2015;23:2109 17. S4.4.4.3-5. Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;116:1032 40. S4.4.4.3-6. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC) Pediatrics. 2001;107:256 64. S4.4.4.3-7. Dorgan JF, Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results of the Dietary Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab. 2011;96:E1999 2008. S4.4.4.3-8. Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric hyper- lipidemia: a placebo-controlled, blinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with hypercholesterolemia. JAMA Pediatr. 2013;167:708 13. S4.4.4.3-9. Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipid- emia and standardized lifestyle modification: benchmarking real- world practice. J Am Coll Cardiol. 2016;68:2122 3. S4.4.4.3-10. Torvik K, Narverud I, Ottestad I, et al. Dietary counseling is associ- ated with an improved lipid profile in children with familial hyper- cholesterolemia. Atherosclerosis. 2016;252:21 7. S4.4.4.3-11. Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterol- emia in children and adolescents. Acta Paediatr. 1992;81:682 5. S4.4.4.3-12. Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of nutrition education for hypercholesterolemic chil- dren. Am J Public Health. 1998;88:258 61. S4.4.4.3-13. Kusters DM, Caceres M, Coll M, et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr. 2015;166:1377 84 e1-3. S4.4.4.3-14. Yeste D, Chacon P, Clemente M, et al. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adoles- cents. J Pediatr Endocrinol Metab. 2009;22:487 92. S4.4.4.3-15. Clauss S, Wai KM, Kavey RE, et al. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr. 2009;154:869 72. S4.4.4.3-16. Sonnett T, Robinson J, Milani P, et al. Role of colesevelam in man- aging heterozygous familial hypercholesterolemia in adolescents and children. Adolesc Health Med Ther. 2010;1:53 60. S4.4.4.3-17. Wald DS, Kasturiratne A, Godoy A, et al. Child-parent screening for familial hypercholesterolemia. J Pediatr. 2011;159:865 7. S4.4.4.3-18. Wald DS, Bestwick JP, Morris JK, et al. Child-parent familial hypercholesterolemia screening in primary care. N Engl J Med. 2016;375:1628 37. S4.4.4.3-19. Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: the CARDIAC project. Pediatrics. 2010;126:260 5. S4.4.4.3-20. Skovby F, Micic S, Jepsen B, et al. Screening for familial hyper- cholesterolaemia by measurement of apolipoproteins in capillary blood. Arch Dis Child. 1991;66:844 7. S4.4.4.3-21. Garcia RE, Moodie DS. Routine cholesterol surveillance in child- hood. Pediatrics. 1989;84:751 5. S4.4.4.3-22. Ned RM, Sijbrands EJ. Cascade screening for familial hypercholes- terolemia (FH) PLoS Curr. 2011;3:RRN1238. S4.4.4.3-23. Bender R, Bell DA, Hooper AJ, et al. Screening for familial hyper- cholesterolaemia. Pathology. 2012;44:122 8. S4.4.4.3-24. National Institute for Health and Care Excellence (NICE) (UK). Familial hypercholesterolaemia: identification and management. Available at: http://www.nice.org.uk/guidance/CG71. Accessed August 24, 2018. S4.4.4.3-25. Kit BK, Kuklina E, Carroll MD, et al. Prevalence of and trends in dyslipidemia and blood pressure among US children and adoles- cents, 1999 2012 JAMA Pediatr. 2015;169:272 9. S4.4.4.3-26. May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular dis- ease risk factors among US adolescents, 1999 2008 Pediatrics. 2012;129:1035 41. S4.4.4.3-27. Lozano P, Henrikson NB, Morrison CC, et al. Lipid screening in childhood and adolescence for detection of multifactorial dys- lipidemia: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316:634 44. S4.4.4.3-28. Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132:2167 92. S4.4.4.3-29. Lozano P, Henrikson NB, Dunn J, et al. Lipid screening in child- hood and adolescence for detection of familial hypercholesterol- emia: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316:645 55. S4.4.4.3-30. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2017;7:CD006401. S4.4.4.3-31. Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvas- tatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64:285 96. S4.4.4.3-32. Ardoin SP, Schanberg LE, Sandborg CI, et al. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis pro- gression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis. 2014;73:557 66. S4.4.4.3-33. Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of ath- erosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype. Circulation. 2016;134:9 19. S4.4.4.3-34. Neil HA, Hawkins MM, Durrington PN, et al. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective regis- try study. Atherosclerosis. 2005;179:293 7. S4.4.4.3-35. Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterol- emia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63:1935 47. S4.4.4.3-36. Smith AJ, Turner EL, Kinra S. Universal cholesterol screening in childhood: a systematic review. Acad Pediatr. 2016;16:716 25. S4.4.4.3-37. Kerr M, Pears R, Miedzybrodzka Z, et al. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. 2017;38:1832 9. CLINICAL STATEMENTS AND GUIDELINES S4.4.4.3-38. Berenson GS. Childhood risk factors predict adult risk associated with subclinical cardiovascular disease. The Bogalusa Heart Study. Am J Cardiol. 2002;90:3L 7L. S4.4.4.3-39. Juonala M, Magnussen CG, Venn A, et al. Influence of age on associations between childhood risk factors and carotid intima- media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation. 2010;122:2514 20. S4.4.4.3-40. Juhola J, Magnussen CG, Viikari JS, et al. Tracking of serum lipid levels, blood pressure, and body mass index from childhood to adulthood: the Cardiovascular Risk in Young Finns Study. J Pediatr. 2011;159:584 90. S4.4.4.3-41. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guide- lines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128 suppl 5: S213 56. S4.4.4.3-42. Gidding SS, Daniels SR, Kavey RE, et al. Developing the 2011 integrated pediatric guidelines for cardiovascular risk reduction. Pediatrics. 2012;129:e1311 9. 4.5. Other Populations at Risk S4.5.1-1. Carnethon MR, Pu J, Howard G, et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation. 2017;136:e393 423. abnormalities among normal-weight persons from five racial/eth- nic groups in the United States: a cross-sectional analysis of two cohort studies. Ann Intern Med. 2017;166:628 36. S4.5.1-3. Rao G, Powell-Wiley TM, Ancheta I, et al. Identification of obesity and cardiovascular risk in ethnically and racially diverse popula- tions: a scientific statement from the American Heart Association. Circulation. 2015;132:457 72. S4.5.1-4. Hata J, Kiyohara Y. Epidemiology of stroke and coronary artery disease in Asia. Circ J. 2013;77:1923 32. S4.5.1-5. Group H-TC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279 91. S4.5.1-6. Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refin- ing myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155 62. S4.5.1-7. Daviglus ML, Pirzada A, Talavera GA. Cardiovascular disease risk factors in the Hispanic/Latino population: lessons from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) Prog Cardiovasc Dis. 2014;57:230 6. S4.5.1-8. Daviglus ML, Pirzada A, Durazo-Arvizu R, et al. Prevalence of low cardiovascular risk profile among diverse Hispanic/Latino adults in the United States by age, sex, and level of tacculturation: the Hispanic Community Health Study/Study of Latinos. J Am Heart Assoc 2016;5:e003929. S4.5.1-9. Gonzalez HM, Tarraf W, Rodriguez CJ, et al. Cardiovascular health among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos (HCHS/SOL) results. Am Heart J. 2016;176:134 44. S4.5.1-10. Qureshi WT, Kaplan RC, Swett K, et al. American College of Cardiology/American Heart Association (ACC/AHA) Class I guidelines for the treatment of cholesterol to reduce ath- erosclerotic cardiovascular risk: implications for US Hispanics/ Latinos based on findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) J Am Heart Assoc 2017:6; e005045. S4.5.1-11. Schneiderman N, Chirinos DA, Aviles-Santa ML, et al. Challenges in preventing heart disease in hispanics: early lessons learned from the Hispanic Community Health Study/Study of Latinos (HCHS/ SOL) Prog Cardiovasc Dis. 2014;57:253 61. S4.5.1-12. Hutchinson RN, Shin S. Systematic review of health disparities for cardiovascular diseases and associated factors among American Indian and Alaska Native populations. PLoS One. 2014:9;e80973. S4.5.1-13. Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epide- miology, risk factors, and treatments: a scientific statement from the American Heart Association. Circulation. 2018;138:e1 34. S4.5.1-14. Conomos MP, Laurie CA, Stilp AM, et al. Genetic diversity and asso- ciation studies in US Hispanic/Latino populations: applications in the Hispanic Community Health Study/Study of Latinos. Am J Hum Genet. 2016;98:165 84. S4.5.1-15. Frank AT, Zhao B, Jose PO, et al. Racial/ethnic differences in dyslipid- emia patterns. Circulation. 2014;129:570 9. S4.5.1-16. Pu J, Romanelli R, Zhao B, et al. Dyslipidemia in special ethnic popu- lations. Cardiol Clin. 2015;33:325 33. S4.5.1-17. Basu S, Hong A, Siddiqi A. Using decomposition analysis to identify modifiable racial disparities in the distribution of blood pressure in the United States. Am J Epidemiol. 2015;182:345 53. S4.5.1-18. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syn- drome based on a harmonious definition among adults in the US. J Diabetes. 2010;2:180 93. S4.5.1-19. Gujral UP, Pradeepa R, Weber MB, et al. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci. 2013;1281:51 63. S4.5.1-20. Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and dif- ferences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281:64 91. S4.5.1-21. Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the United States, 1988 2012 JAMA. 2015;314:1021 9. S4.5.1-22. DeFilippis AP, Young R, McEvoy JW, et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive thera- pies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38:598 608. S4.5.1-23. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49 73. S4.5.1-24. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311:1406 15. S4.5.1-25. Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the atheroscle- rotic cardiovascular risk equation in a large contemporary, multieth- nic population. J Am Coll Cardiol. 2016;67:2118 30. S4.5.1 26. Kandula NR, Kanaya AM, Liu K, et al. Association of 10-year and lifetime predicted cardiovascular disease risk with subclinical atherosclerosis in South Asians: findings from the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. J Am Heart Assoc. 2014:3;e001117. S4.5.1-27. Alluri K, McEvoy JW, Dardari ZA, et al. Distribution and burden of newly detected coronary artery calcium: results from the Multi- Ethnic Study of Atherosclerosis. J Cardiovasc Comput Tomogr. 2015;9:337 344.e1. S4.5.1 28. Cho YK, Jung CH, Kang YM, et al. 2013 ACC/AHA cholesterol guideline versus 2004 NCEP ATP III guideline in the prediction of coronary artery calcification progression in a Korean Population. J Am Heart Assoc 2016;5:e003410. S4.5.1-29. Manolio TA, Arnold AM, Post W, et al. Ethnic differences in the relationship of carotid atherosclerosis to coronary calcifica- tion: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2008;197:132 8. S4.5.1-30. Osawa K, Nakanishi R, Budoff M. Coronary artery calcification. Glob Heart. 2016;11:287 93. S4.5.1-31. Kanaya AM, Kandula NR, Ewing SK, et al. Comparing coronary artery calcium among US South Asians with four racial/ethnic groups: the MASALA and MESA studies. Atherosclerosis. 2014;234:102 7. S4.5.1-32. Greenland P, Blaha MJ, Budoff MJ, et al. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72:434 47. S4.5.1-33. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of car- diovascular disease with pravastatin in Japan (MEGA Study): a pro- spective randomised controlled trial. Lancet. 2006;368:1155 63. S4.5.1-34. Kimura T, Inoue T, Taguchi I, et al. Does high-intensity pitavastatin therapy further improve clinical outcomes? The REAL-CAD study CLINICAL STATEMENTS AND GUIDELINES in 13054 patients with stable coronary artery disease. Circulation 2017:136;e450. S4.5.1-35. Birmingham BK, Bujac SR, Elsby R, et al. Rosuvastatin pharmacoki- netics and pharmacogenetics in Caucasian and Asian subjects resid- ing in the United States. Eur J Clin Pharmacol. 2015;71:329 40. S4.5.1-36. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330 41. S4.5.1-37. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99:410 4. S4.5.1-38. Lloret R, Ycas J, Stein M, et al. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial) Am J Cardiol. 2006;98:768 73. S4.5.1-39. George MD, McGill NK, Baker JF. Creatine kinase in the US popula- tion: Impact of demographics, comorbidities, and body composition on the normal range. Medicine (Baltimore). 2016;95:e4344. S4.5.2-1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce ath- erosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. S4.5.2-2. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213 9. S4.5.2-3. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Jama. 2007;298:299 308. S4.5.2-4. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglyc- erides and risk of ischemic stroke in the general population. Jama. 2008;300:2142 52. S4.5.2-5. Karlson BW, Palmer MK, Nicholls SJ, et al. A VOYAGER meta-anal- ysis of the impact of statin therapy on low-density lipoprotein cho- lesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016;117:1444 8. S4.5.2-6. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581 90. S4.5.2-7. Christian JB, Arondekar B, Buysman EK, et al. Clinical and eco- nomic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012;6:450 61. S4.5.2-8. Duane WC, Hunninghake DB, Freeman ML, et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers choles- terol saturation index of gallbladder bile. Hepatology. 1988;8: 1147 50. S4.5.2-9. Rhodes KS, Weintraub M, Marchlewicz EH, et al. Medical nutri- tion therapy is the essential cornerstone for effective treatment of refractory severe hypertriglyceridemia regardless of pharmaceuti- cal treatment: evidence from a lipid management program. J Clin Lipidol. 2015;9:559 67. S4.5.2-10. Greenberg BH, Blackwelder WC, Levy RI. Primary type V hyperlipo- proteinemia. A descriptive study in 32 families. Ann Intern Med. 1977;87:526 34. S4.5.2-11. Steiner G, Adelman AG, Silver MD. Early coronary atheroscle- rosis in primary type V hyperlipoproteinemia. Can Med Assoc J. 1971;105:1172 4. S4.5.2-12. Neil HA, Cooper J, Betteridge DJ, et al. All-cause and cardiovas- cular mortality in treated patients with severe hypertriglyceri- daemia: a long-term prospective registry study. Atherosclerosis. 2010;211:618 23. S4.5.2-13. Christian JB, Arondekar B, Buysman EK, et al. Determining triglycer- ide reductions needed for clinical impact in severe hypertriglyceride- mia. Am J Med. 2014;127:36 44 e1. S4.5.2-14. Chait A, Brunzell JD. Severe hypertriglyceridemia: role of familial and acquired disorders. Metabolism. 1983;32:209 14. S4.5.2-15. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglycer- ide levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial) Am J Cardiol. 2011;108:682 90. S4.5.2-16. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular dis- ease: a scientific statement from the American Heart Association. Circulation. 2016;134:e468 95. S4.5.2-17. Basar R, Uzum AK, Canbaz B, et al. Therapeutic apheresis for severe hypertriglyceridemia in pregnancy. Arch Gynecol Obstet. 2013;287:839 43. 4.5.3. Issues Specific to Women S4.5.3-1. Ouyang P, Wenger NK, Taylor D, et al. Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists. Biol Sex Differ. 2016;7:19. S4.5.3-2. Grandi SM, Vallee-Pouliot K, Reynier P, et al. Hypertensive disorders in pregnancy and the risk of subsequent cardiovascular disease. Paediatr Perinat Epidemiol. 2017;31:412 21. S4.5.3-3. Shostrom DCV, Sun Y, Oleson JJ, et al. History of gestational diabe- tes mellitus in relation to cardiovascular disease and cardiovascular risk factors in US women. Front Endocrinol (Lausanne). 2017;8:144. S4.5.3-4. Catov JM, Newman AB, Roberts JM, et al. Preterm delivery and later maternal cardiovascular disease risk. Epidemiology. 2007;18:733 9. S4.5.3-5. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1:767 76. S4.5.3-6. Roeters van Lennep JE, Heida KY, Bots ML, et al. Cardiovascular dis- ease risk in women with premature ovarian insufficiency: A system- atic review and meta-analysis. Eur J Prev Cardiol. 2016;23:178 86. S4.5.3-7. Edison RJ, Muenke M. Central nervous system and limb anoma- lies in case reports of first-trimester statin exposure. N Engl J Med. 2004;350:1579 82. S4.5.3-8. Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol. 2007;64:496 509. S4.5.3-9. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG- CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008;26:175 7. S4.5.3-10. Winterfeld U, Allignol A, Panchaud A, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG. 2013;120:463 71. S4.5.3-11. Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2014;36:506 9. S4.5.3-12. McGrogan A, Snowball J, Charlton RA. Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss. Pharmacoepidemiol Drug Saf. 2017;26:843 52. S4.5.3-13. Fulcher J, O Connell R, Voysey M, et al. Efficacy and safety of LDL- lowering therapy among men and women: meta-analysis of individ- ual data from 174000 participants in 27 randomised trials. Lancet. 2015;385:1397 405. S4.5.3 14. Ley SH, Li Y, Tobias DK, et al. Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of car- diovascular disease in women. J Am Heart Assoc 2017;6;e006713. S4.5.3-15. Costantine MM, Cleary K, Hebert MF, et al. Safety and pharmaco- kinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214:720.e1 e17. S4.5.3-16. Toleikyte I, Retterstol K, Leren TP, et al. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation. 2011;124:1606 14. S4.5.3-17. Sanderson SL, Iverius PH, Wilson DE. Successful hyperlipemic preg- nancy. JAMA. 1991;265:1858 60. 4.5.4 Adults With CKD S4.5.4-1. Cholesterol Treatment Trialists (CTT) Collaboration, Herrington W, Emberson J, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4:829 39. S4.5.4-2. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181 92. CLINICAL STATEMENTS AND GUIDELINES S4.5.4-3. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and car- diovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395 407. S4.5.4-4. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238 48. S4.5.4-5. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in peo- ple with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807 14. S4.5.4-6. Matsushita K, van der Velde M, Astor BC, et al. Association of esti- mated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collabora- tive meta-analysis. Lancet. 2010;375:2073 81. S4.5.4-7. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbumin- uria. Circulation. 2004;110:2809 16. 4.5.5. Adults With Chronic Inflammatory Disorders and HIV S4.5.5-1. Mantel A, Holmqvist M, Jernberg T, et al. Rheumatoid arthritis is asso- ciated with a more severe presentation of acute coronary syndrome and worse short-term outcome. Eur Heart J. 2015;36:3413 22. S4.5.5-2. Douglas KM, Pace AV, Treharne GJ, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syn- drome. Ann Rheum Dis. 2006;65:348 53. S4.5.5-3. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70:929 34. S4.5.5-4. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovas- cular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690 7. S4.5.5-5. Wajed J, Ahmad Y, Durrington PN, et al. Prevention of cardiovascu- lar disease in systemic lupus erythematosus proposed guidelines for risk factor management. Rheumatology (Oxford). 2004;43:7 12. S4.5.5-6. Westerweel PE, Luyten RK, Koomans HA, et al. Premature athero- sclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum. 2007;56:1384 96. S4.5.5-7. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31:1000 6. S4.5.5-8. Hanna DB, Ramaswamy C, Kaplan RC, et al. Trends in cardiovas- cular disease Mortality among persons with HIV in New York City, 2001 2012 Clin Infect Dis. 2016;63:1122 9. S4.5.5-9. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506 12. S4.5.5-10. Kearns A, Gordon J, Burdo TH, et al. HIV-1-associated atherosclero- sis: unraveling the missing link. J Am Coll Cardiol. 2017;69:3084 98. S4.5.5-11. Dregan A, Chowienczyk P, Molokhia M. Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders. Heart. 2017;103:1867 73. S4.5.5-12. Fernandez-Montero JV, Barreiro P, de Mendoza C, et al. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral Hepat. 2016;23:47 52. S4.5.5-13. Bartels CM, Kind AJ, Everett C, et al. Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. Arthritis Rheum. 2011;63:1221 30. S4.5.5-14. Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for sub- stantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis. 2010;69:683 8. S4.5.5-15. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretro- viral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993 2003. S4.5.5-16. Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refin- ing myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155 62. S4.5.5-17. Arts EE, Popa C, Den Broeder AA, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis. 2015;74:668 74. S4.5.5-18. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insu- lin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35 43. S4.5.5-19. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected par- ticipants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45: 111 9. S4.5.5-20. Davis JM 3rd, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population- based cohort study. Arthritis Rheum. 2007;56:820 30. S4.5.5-21. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482 7. S4.5.5-22. Ronda N, Favari E, Borghi MO, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythema- tosus. Ann Rheum Dis. 2014;73:609 15. S4.5.5-23. Navarro-Millan I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 2013;65:1430 8. 5. STATIN SAFETY AND STATIN- ASSOCIATED SIDE EFFECTS S5-1. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013:CD004816. S5-2. Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discus- sion for atherosclerotic cardiovascular disease prevention: impor- tance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol. 2015;65:1361 8. S5-3. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96 103. S5-4. Gupta A, Thompson D, Whitehouse A, et al. Adverse events asso- ciated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017;389:2473 81. S5-5. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and toler- ability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580 90. S5-6. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758 69. S5-7. Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014;160:301 10. S5-8. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analy- sis from the JUPITER trial. Lancet. 2012;380:565 71. S5-9. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556 64. S5-10. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735 42. S5-11. Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111:1123 30. S5-12. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metfor- min. N Engl J Med. 2002;346:393 403. S5-13. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012 22. S5-14. Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. J Am Coll Cardiol. 2016;67:2395 410. CLINICAL STATEMENTS AND GUIDELINES S5-15. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce ath- erosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. S5-16. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916 22. S5-17. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011;106:71 7. S5-18. Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coro- nary heart disease patients with mild-to-moderate baseline eleva- tions in alanine aminotransferase levels. Int J Cardiol. 2013;168: 3846 52. S5-19. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68:92 125. S5-20. Taylor BA, Lorson L, White CM, et al. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238:329 35. S5-21. Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90:24 34. S5-22. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S5-23. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388: 2532 61. S5-24. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in inter- mediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021 31. S5-25. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate mus- cular symptoms with high-dosage statin therapy in hyper- lipidemic patients the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403 14. S5-26. Cohen JD, Brinton EA, Ito MK, et al. Understanding statin Use in America and Gaps in Patient Education (USAGE): an Internet-based survey of 10138 current and former statin users. J Clin Lipidol. 2012;6:208 15. S5-27. Serban MC, Colantonio LD, Manthripragada AD, et al. Statin Intolerance and Risk of Coronary Heart Events and All-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386 95. S5-28. Zhang H, Plutzky J, Shubina M, et al. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med. 2017;167:221 7. S5-29. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526 34. S5-30. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6 15. S5-31. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597 603. S5-32. Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374:664 9. S5-33. Richardson K, Schoen M, French B, et al. Statins and cogni- tive function: a systematic review. Ann Intern Med. 2013;159: 688 97. S5-34. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49 73. S6-1. Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 1997;80:111 5. S6-2. Tamblyn R, Reidel K, Huang A, et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Med Decis Making. 2010;30:176 88. S6-3. Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combina- tion strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310:918 29. S6-4. van Driel ML, Morledge MD, Ulep R, et al. Interventions to improve adherence to lipid-lowering medication. Cochrane Database Syst Rev. 2016;12:CD004371. S6-5. Chan WV, Pearson TA, Bennett GC, et al. ACC/AHA special report: clinical practice guideline implementation strategies: a summary of systematic reviews by the NHLBI Implementation Science Work Group: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e122 37. S6-6. Fischer F, Lange K, Klose K, et al. Barriers and strategies in guideline implementation a scoping review. Healthcare (Basel) 2016;4. S6-7. Stacey D, Hill S, McCaffery K, et al. Shared decision making inter- ventions: theoretical and empirical evidence with implications for health literacy. Stud Health Technol Inform. 2017;240:263 83. S6-8. Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431. S6-9. Cabana MD, Rand CS, Powe NR, et al. Why don t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458 65. S6-10. Pokharel Y, Tang F, Jones PG, et al. Adoption of the 2013 American College of Cardiology/American Heart Association cholesterol management guideline in cardiology practices nationwide. JAMA Cardiol. 2017;2:361 9. S6-11. Rodriguez F, Lin S, Maron DJ, et al. Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: practice impact of the new cholesterol guide- lines. Am Heart J. 2016;182:97 102. S6-12. Pokharel Y, Gosch K, Nambi V, et al. Practice-level variation in statin use among patients with diabetes: insights from the PINNACLE Registry. J Am Coll Cardiol. 2016;68:1368 9. S6-13. Hira RS, Cowart JB, Akeroyd JM, et al. Risk factor optimization and guideline-directed medical therapy in US veterans with peripheral arterial and ischemic cerebrovascular disease compared to veterans with coronary heart disease. Am J Cardiol. 2016;118:1144 9. S6-14. Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic dis- eases in the United States: a systematic review. Ann Intern Med. 2012;157:785 95. S6-15. Slejko JF, Ho M, Anderson HD, et al. Adherence to statins in primary prevention: yearly adherence changes and outcomes. J Manag Care Pharm. 2014;20:51 7. S6-16. Zimolzak AJ, Spettell CM, Fernandes J, et al. Early detection of poor adherers to statins: applying individualized surveillance to pay for performance. PLoS One 2013:8;e79611. S6-17. Bitton A, Choudhry NK, Matlin OS, et al. The impact of medica- tion adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med. 2013;126:357. e7 .e27. S6-18. Korhonen MJ, Robinson JG, Annis IE, et al. Adherence tradeoff to multiple preventive therapies and all-cause mortality after acute myocardial infarction. J Am Coll Cardiol. 2017;70:1543 54. S6-19. Dragomir A, Cote R, White M, et al. Relationship between adher- ence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health. 2010;13:87 94. S6-20. Zhao Y, Zabriski S, Bertram C. Associations between statin adher- ence level, health care costs, and utilization. J Manag Care Spec Pharm. 2014;20:703 13. S6-21. Happe LE, Clark D, Holliday E, et al. A systematic literature review assessing the directional impact of managed care formulary restric- tions on medication adherence, clinical outcomes, economic CLINICAL STATEMENTS AND GUIDELINES outcomes, and health care resource utilization. J Manag Care Spec Pharm. 2014;20:677 84. S6-22. Drozda JP Jr, Ferguson TB Jr, Jneid H, et al. 2015 ACC/AHA focused update of secondary prevention lipid performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circ Cardiovasc Qual Outcomes. 2016;9:68 95. S6-23. Krones T, Keller H, Sonnichsen A, et al. Absolute cardiovascular dis- ease risk and shared decision making in primary care: a randomized controlled trial. Ann Fam Med. 2008;6:218 27. S6-24. ASCVD Risk Estimator Plus. Available at: http://tools.acc.org/ASCVD- Risk-Estimator-Plus/#!/calculate/estimate/. Accessed September 1, 2018. S6-25. Statin Choice Decision Aid. Available at: https://statindecisionaid. mayoclinic.org/. Accessed October 13, 2018. S6-26. Barry MJ, Edgman-Levitan S. Shared decision making pinnacle of patient-centered care. N Engl J Med. 2012;366:780 1. S6-27. Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Med Decis Making. 2015;35:114 31. S6-28. Using Motivational Interviewing to Create Change. Available at: http:// tCookieSupport=1. Accessed March 27, 2018. 7. COST AND VALUE CONSIDERATIONS 7.1. Economic Value Considerations: S7.1-1. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state- ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329 45. S7.1-2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clini- cal outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713 22. S7.1-3. Hlatky MA, Kazi DS. PCSK9 Inhibitors: economics and policy. J Am Coll Cardiol. 2017;70:2677 87. S7.1-4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267 78. S7.1-5. Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of evo- locumab therapy for reducing cardiovascular events in patients with ath- erosclerotic cardiovascular disease. JAMA Cardiol. 2017;2:1069 78. S7.1-6. Robinson JG, Huijgen R, Ray K, et al. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol. 2016;68:2412 21. S7.1-7. Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercho- lesaaaaaaaaterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316:743 53. S7.1-8. Gandra SR, Villa G, Fonarow GC, et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. 2016;39:313 20. S7.1-9. Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness thresholds. Geneva, Switzerland: World Health Organization, 2009. 8. LIMITATIONS AND KNOWLEDGE GAPS 8.2. Risk Assessment S8.2-1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce ath- erosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. CLINICAL STATEMENTS AND GUIDELINES Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/ NLA/PCNA Guideline on the Management of Blood Cholesterol* (August 2018) Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Scott M. Grundy Chair VA North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas Professor of Internal Medicine None None None None None None Neil J. Stone Vice Chair Northwestern Medicine/Northwestern University Bonow Professor of Medicine, Cardiology None None None None None None Alison L. Bailey Erlanger Health System/University of Tennessee College of Medicine Program Director, Cardiovascular Diseases Fellowship; Director, Preventive cardiology and Cardiac Rehabilitation None None None None None None Craig Beam CBRE Managing Director; National Cultivation/Strategic Investments Leader None None None None None None Kim K. Birtcher University of Houston College of Pharmacy Clinical Professor None None None None None None Roger S. Blumenthal Johns Hopkins University, Ciccarone Center for the Prevention of Heart Disease Professor of Medicine None None None None None None Lynne T. Braun Rush University Medical Center Professor of Nursing and Medicine None None None None None None Sarah De Ferranti Boston Children s Hospital Assistant Professor of Pediatrics None None None None None None Joseph Faiella- Tommasino Touro College, School of Health Sciences Chairman and Assistant Dean of Physician Assistant Programs None None None None None None Daniel E. Forman University of Pittsburgh Chair, Geriatric Cardiology None None None None None None Ronald Goldberg University of Miami, Diabetes Research Institute Professor of Medicine, Division of Endocrinology, Metabolism and Diabetes None None None None None None Paul A. Heidenreich Stanford University, Department of Medicine Professor, Vice Chair for Quality None None None None None None Mark A. Hlatky Stanford University, School of Medicine Professor of Health Research Policy, Professor of Cardiovascular Medicine None None None None None None Daniel W. Jones University of Mississippi Medical Center Professor of Medicine and Physiology; Director, Clinical and Population Science None None None None None None Donald Lloyd-Jones Northwestern University Eileen M. Foell Professor; Chair, Department of Preventive Medicine None None None None None None Nuria Lopez-Pajares Temple University Physician None None None None None None Chiadi Ndumele Johns Hopkins University School of Medicine Robert E. Meyerhoff Assistant Professor of Medicine None None None None None None Carl E. Orringer University of Miami, Soffer Clinical Research Center Associate Professor None None None None None None Carmen Peralta University of California, San Francisco Associate Professor of Medicine; Kidney Health Research Collaborative Executive Director None None None None None None (Continued) CLINICAL STATEMENTS AND GUIDELINES Joseph Saseen University of Colorado, Anschutz Medical Campus Professor and Vice Chair, Department of Clinical Pharmacy; Professor, Department of Family Medicine None None None None None None Sidney C. Smith, Jr University of North Carolina, Chapel Hill Professor of Medicine None None None None None None Laurence S. Sperling Emory University, Rollins School of Public Health Professor of Medicine, Cardiology; Professor of Global Health None None None None None None Salim S. Virani Baylor College of Medicine Professor, Section of Cardiovascular Research and Director, Cardiology Fellowship Training Program; Michael E. DeBakey VA Medical Center Staff Cardiologist and Investigator, Health Policy, Quality & Informatics Program, Center for Innovations in Quality, Effectiveness and Safety None None None None None None Joseph Yeboah Wake Forest Baptist Health Assistant Professor, Internal Medicine, Cardiovascular None None None None None None This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/ AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document or makes a competing drug or device addressed in the document; or c) the person or a member of the person s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. *The Cholesterol Guideline began in September 2016. Over the initial years of the CMS Open Payment System, understandably, there have been many issues related to the accurate reporting of food and beverage payments. For this reason, the ACC and AHA have not considered these minor charges relevant relationships with industry. AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AAPA, American Academy of Physician Assistants; ABC, Association of Black Cardiologists; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; ADA, American Diabetes Association; AGS, American Geriatrics Society; AHA, American Heart Association; APhA, American Pharmacists Association; ASPC, American Society for Preventive Cardiology; PCNA, Preventive Cardiovascular Nurses Association; and VA, Veterans Affairs. Appendix 1. Continued Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness CLINICAL STATEMENTS AND GUIDELINES Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (August 2018) Peer Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Salary Philip A. Ades Official Reviewer AACVPR University of Vermont Medical Center Professor of Medicine None None None None None None None Karen P. Alexander Official Reviewer ACC Science and Quality Committee Duke University Medical Center Professor of Medicine/Cardiology None None None GSK NIH None None None Theresa M. Beckie Official Reviewer AACVPR University of South Florida Professor and Associate Dean of the PhD Program None None None None None None None Kathy Berra Official Reviewer PCNA Stanford University Omada Health None None None Council on Aspirin for Health and Prevention - a committee of the Altarum Institute Preventive Cardiovascular Nurses Association None None William T. Cefalu Official Reviewer ADA American Diabetes Association Chief Scientific, Medical and Mission Officer None None None None None None None Mary Ann Champagne Official Peer Reviewer PCNA Stanford Hospital and Clinics Clinical Nurse Specialist and Coordinator None None None None None None None Joaquin Cigarroa Official Reviewer ACC/AHA Task Force on Clinical Practice Guidelines Oregon Health and Science University Clinical Professor of Medicine None None None None None None None Stephen R. Daniels Official Reviewer AAP University of Colorado School of Medicine Professor and Chair, Department of Pediatrics; Children s Hospital Colorado Pediatrician- in-Chief and L. Joseph Butterfield Chair in Pediatrics Sanofi-Aventis None None None Novo Nordisk Inc. None None Dave Dixon Official Reviewer NLA Virginia Commonwealth University School of Pharmacy Associate Professor and Vice-Chair for Clinical Services None None None None None None None Earl W. Ferguson Official Reviewer ACPM Ridgecrest Regional Hospital Independent Consultant None None Bakersfield Heart Hospital None Growth Creators Inc./Radekal/ Pertexa California Health Information Partnership and Services Organization None None Edward A. Gill, Jr Official Reviewer NLA University of Colorado Cardiology Division Professor of Clinic Practice, Medicine- Cardiology None None None None None None Acute Coronary Syndrome Tyler J. Gluckman Official Reviewer ACC Board of Governors Providence St. Vincent Heart Clinic Medical Director Boehringer Ingelheim Pharmaceuticals None None None None None None Rita Kalyani Official Reviewer ADA Johns Hopkins School of Medicine Associate Professor of Medicine None None None None None None None Norma M. Keller Official Reviewer ACC Board of Governors New York University Medical Center Chief of Cardiology None None None None None None None Amit Khera Official Reviewer ASPC University of Texas Southwestern Medical Center Assistant Professor of Medicine None None None None None None None (Continued) CLINICAL STATEMENTS AND GUIDELINES Carol Kirkpatrick Official Reviewer NLA Idaho State University Wellness Center Director/ Clinical Associate Professor Kasiska Division of Health Sciences National Lipid Association None None None None None None G. B. John Mancini Official Reviewer ACC Board of Governors Vancouver Hospital Research Pavilion Professor of Medicine Amgen Bayer Boehringer Ingelheim Pharmaceuticals, Inc Eli Lilly and Company Esperion Merck Pfizer Regeneron Sanofi-aventis/ Regeneron Servier None None None None None None Laxmi S. Mehta Official Reviewer ACC Science and Quality Committee Ohio State University Professor of Medicine; Section Director of Preventative Cardiology and Women s Cardiovascular Health None None None None AHA None None David Montgomery Official Reviewer ABC Piedmont Heart Institute Cardiologist None None None None None None None Michelle Odden Official Reviewer AGS Oregon State University Associate Professor None None None None None None None Daniel J. Rader Official Reviewer AHA Cooper-McClure Professor of Medicine; University of Pennsylvania School of Medicine Director, Preventive Cardiovascular Medicine Alnylam* Novartis* Pfizer* DalCor MedImmune, Inc None Staten Bio* VascularStrategies* None None None None Michael W. Rich Official Reviewer AGS Washington University School of Medicine Professor of Medicine None None None None None None None Mirvat A. Alasnag Content Reviewer ACC Early Career Member Section King Fahd Armed Forces Hospital, Jeddah- KSA Interventional Cardiologist None None None None None None None Kim K. Birtcher Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines University of Houston College of Pharmacy Clinical Professor Jones & Bartlett Learning None None None Accreditation Council for Clinical Lipidology None Conrad B. Blum Content Reviewer ACC/AHA Medicine at Columbia University Medical Center Professor None None None None ACC-AHA None None Bernard Dennis Content Reviewer ACC/AHA Lay Reviewer Dennis Associates, LLC None None None None None None None Henry Ginsberg Content Reviewer AHA Columbia University, Irving Professor of Medicine Merck Resverlogix Sanofi- Regeneron Amgen Akcea Kowa Janssen Esperion None None None None None None Ira Goldberg Content Reviewer AHA NYU Division of Endocrinology, Diabetes, and Metabolism Director Akcea* Amgen Arrowhead Intarcia Merck Regeneron None None None None None None Jos A. Joglar Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines UT Southwestern Medical Center University Professor of Medicine None None None None None None None Appendix 2. Continued Peer Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Salary (Continued) CLINICAL STATEMENTS AND GUIDELINES Glenn N. Levine Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines Baylor College of Medicine Professor of Medicine; Michael E. DeBakey Medical Center Director, Cardiac Care Unit None None None None None Defendant, Out-of-hospital cardiopulmonary None Daniel Levy Content Reviewer ACC/AHA Center for Population Studies Director; Journal of the American Society of Hypertension Editor- in-Chief None None None None None None None Theodore Mazzone Content Reviewer ACC/AHA NorthShore University Health System Chairman, Department of Medicine None None None None None None None Patrick E. McBride Content Reviewer ACC/AHA University of Wisconsin School of Medicine and Public Health Professor Emeritus, Departments of Medicine (Cardiovascular Medicine) and Family Medicine None None Health Decisions, Inc None None None None Karen J. McConnell Content Reviewer APhA Catholic Health Initiatives System Director of Clinical Pharmacy Services None None None None None None None Pamela B. Morris Content Reviewer ACC Prevention of Cardiovascular Disease Member Section The Medical University of South Carolina Professor of Medicine, Director of Preventative Cardiology Amgen Esperion Sanofi Regeneron None None None None None None Nathalie Pamir Content Reviewer AHA Scientific Council Oregon Health and Science University Assistant Professor None None None None None None None Janelle F. Ruisinger Content Reviewer APhA The University of Kansas School of Pharmacy, Department of Pharmacy Practice Clinical Pharmacist; KUMC Atherosclerosis and LDL-Apheresis Center Clinical Associate Professor None None None Amgen Regeneron Sanofi- Aventis American Society of Health System Pharmacists None None Joshua Schulman- Marcus Content Reviewer ACC Early Career Member Section Albany Medical Center Assistant Professor of Medicine None None None None None None None Michael D. Shapiro Content Reviewer ACC Prevention of Cardiovascular Disease Member Section Oregon Health & Science University Associate Professor of Medicine and Radiology Akcea Amgen Kastle* Novartis Corporation Regeneron None None Akcea Amarin Amgen None None None Susan Shero Content Reviewer ACC/AHA NIHNHLBI Public Health Advisor None None None None None None None James L. Young II Content Reviewer AHA Beaumont Health Patient/Family Liaison None None None None None None None This table represents all relationships of reviewers with industry and other entities that were reported at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees. *Significant relationship. No financial benefit. AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AAPA, American Academy of Physician Assistants; ABC, Association of Black Cardiologists; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; ADA, American Diabetes Association; AGS, American Geriatrics Society; AHA, American Heart Association; APhA, American Pharmacists Association; ASPC, American Society for Preventive Cardiology; GSK, GlaskoSmithKline; KSA, Kingdom of Saudi Arabia; KUMC, University of Kansas Medical Center; LDL, low-density lipoprotein; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; NLA, National Lipid Association; NYU, New York University; PCNA, Preventive Cardiovascular Nurses Association; and UT, University of Texas. Appendix 2. Continued Peer Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Salary